Alto Neuroscience, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Alto Neuroscience, Inc. (ANRO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $14.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-16
- Alto Neuroscience, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $14.70M, a 2.08% increase from fiscal 2024.
- Alto Neuroscience, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $14.40M, a 28.57% increase from fiscal 2023.
- Alto Neuroscience, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $11.20M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $14.70M 10-K · filed 2026-03-16 |
| 2024-12-31 | $14.40M 10-K · filed 2026-03-16 |
| 2023-12-31 | $11.20M 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |